Drug discovery and development requires a broad array of skills and capabilities.

At Metabolex, we emphasize a cross functional approach, so that what we learn in clinical development is applied to our discovery programs and vice versa.
 
 
  Home > Partnering  
Metabolex has maintained an exclusive focus on diabetes and other metabolic diseases, making it one of the most experienced biotechnology companies in the space. To help move our technologies from the bench to the bedside, we have partnered with some of the world’s largest pharmaceutical companies. Among the companies now working with our proprietary techniques, targets and compounds:
Johnson & Johnson: In 2006, we entered into a comprehensive global strategic agreement with Ortho-McNeil, Inc., a Johnson & Johnson company, to collaborate on the development and commercialization of multiple programs addressing metabolic diseases, including type 2 diabetes, obesity and dyslipidemia. Ortho-McNeil gained exclusive licenses for worldwide development and commercialization of our two clinical compounds, MBX-102 and MBX-2044, and additional follow-on compounds. Metabolex received an exclusive license to a PPAR-delta agonist program, including MBX-8025, which has completed Phase 1b clinical testing, and a cannabinoid receptor-1 (CB-1) inverse agonist clinical program, which targets obesity. We also have a target collaboration in which the two companies will work together to screen metabolic disease targets identified by Metabolex.
Pfizer: We are working with the world’s largest pharmaceutical company to identify targets that play a role in the function of the insulin-producing beta cells in the pancreas, a promising approach to identifying drugs to treat type 2 diabetes and other metabolic diseases.
Astellas: Metabolex and Astellas are working to discover and validate novel drug screening targets identified through Metabolex’s proprietary database of human genes associated with insulin resistance and obesity.